eligibility_summary
Adults with multiple myeloma per IMWG, measurable disease, ECOG 0–1, progressed during/after last regimen, and heavily pretreated (≥3 prior lines, exposed to IMiD, PI, anti‑CD38 mAb, and anti‑BCMA). Excludes CNS MM, active serious infections at leukapheresis (incl severe infection/sepsis/bacteremia within 28 days), prior GPRC5D‑directed therapy or inadequate washout, and other protocol exclusions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, open-label, single-arm trial of arlocabtagene autoleucel (BMS‑986393, CC‑95266, “Arlo‑cel”), an autologous, gene‑modified CAR T‑cell therapy targeting GPRC5D for relapsed/refractory multiple myeloma. Mechanism: patient T cells are engineered to express a chimeric antigen receptor that binds GPRC5D on myeloma cells, triggering T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of tumor cells. Type: biological/cell therapy (autologous CAR T). Targets: GPRC5D antigen on malignant plasma cells, engages T‑cell receptor signaling and immune effector pathways. Population: adults with RRMM after prior IMiD, PI, anti‑CD38 mAb, and anti‑BCMA therapy. Two experimental cohorts, endpoints focus on efficacy and safety.